U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT06812858) titled 'PD-1 Inhibitors Maintenance for CHL Post-autoHCT' on Feb. 02.
Brief Summary: This phase II study is designed to determine the clinical efficacy of PD-1 inhibitors, administered as maintenance therapy after autologous stem cell transplant (autoHCT), in patients with relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL)
Study Start Date: Sept. 02, 2024
Study Type: INTERVENTIONAL
Condition:
Hodgkin Lymphoma
Intervention:
DRUG: Nivolumab, Pembrolizumab
The choice of drug and its dose for maintenance therapy is at the discretion of the study centre (e.g. nivolumab, pembrolizumab). Maintenance therapy should be initiated no ...